CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.

Wen, Jiachen; Wang, Siyuan; Guo, Rongxian; Liu, Dan

Wen, Jiachen; Wang, Siyuan; Guo, Rongxian; Liu, Dan.

Affiliation

Wen J; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: jiachen.a.wen@outlook.com.
Wang S; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Guo R; Institute for the Animal Health Industry of Yangzhou University, Wuxi Zodolabs Biotech Co. Ltd, Wuxi, 214000, China.
Liu D; Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: sammyld@163.com.

Eur J Med Chem ; 245(Pt 1): 114884, 2023 Jan 05.

Article de En | MEDLINE | ID: mdl-36335744

Sujet(s)
Mots clés

Anti-tumor; CSF1R; Immunotherapy; Receptor tyrosine kinase; Tumor-associated macrophage

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteur de facteur de croissance granulocyte-macrophage / Récepteurs à activité tyrosine kinase / Immunothérapie / Tumeurs / Antinéoplasiques Limites: Humans Langue: En Journal: Eur J Med Chem Année: 2023 Type de document: Article Pays de publication: France

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google